DePuy Orthopaedics, Inc. (Depuy), announced that the Orthopaedic and Rehabilitation Devices Advisory Committee of the US Food and Drug Administration (FDA) has unanimously recommended FDA approval of the Pinnacle CoMplete Acetabular Hip System, the first ceramic-on-metal hip bearing to be considered for approval in the US.

The panel’s recommendation was based in part on results from a two-year controlled, randomized, blinded, prospective, multicenter, non-inferiority clinical study and laboratory testing that compared the safety and effectiveness of the Pinnacle CoMplete System to a commonly used DePuy metal-on-metal implant.

The clinical study showed no significant difference in adverse events, revision rates and survivorship after two years, and patients experienced similar pain relief, improved function and range of motion. Laboratory testing on the Pinnacle CoMplete System showed a greater than 90 percent reduction in wear compared to the metal-on-metal system under normal gait conditions and a more than 80 percent reduction in wear under adverse conditions

“We are pleased with the panel’s recommendation, and if approved by the FDA, the Pinnacle CoMplete System would represent an important innovation for hip replacement in the United States,” said Pamela Plouhar, Ph.D., vice president, worldwide clinical affairs, DePuy Orthopaedics, Inc. “Each new implant provides orthopaedic surgeons and their patients more choices, which result in more individualized treatment based on specific patient anatomy, lifestyle, age, medical condition and surgeon preference.”

If approved by the FDA, the Pinnacle CoMplete System would be used in adult patients who suffer from severe pain and disability due to osteoarthritis or post-traumatic arthritis. Conditions for approval recommended by the panel include refinements to the proposed product labeling and a post-approval study.

The Pinnacle CoMplete System is currently an investigational device limited by US law to investigational use only.